ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 147 filers reported holding ENANTA PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.02 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $46,513,000 | +9.7% | 896,724 | 0.0% | 0.99% | -12.2% |
| Q2 2022 | $42,389,000 | -38.2% | 896,724 | -7.0% | 1.13% | -24.6% |
| Q1 2022 | $68,633,000 | +593.8% | 964,212 | +285.7% | 1.50% | +28.1% |
| Q3 2014 | $9,893,000 | -85.1% | 250,000 | -83.8% | 1.17% | -82.6% |
| Q2 2014 | $66,310,000 | +7.6% | 1,539,586 | -0.1% | 6.70% | +51.7% |
| Q1 2014 | $61,628,000 | +697.9% | 1,541,078 | +253.3% | 4.42% | +331.6% |
| Q2 2013 | $7,724,000 | – | 436,145 | – | 1.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 624,768 | $29,533,000 | 9.76% |
| Fairmount Funds Management LLC | 469,264 | $22,182,000 | 5.08% |
| Foresite Capital Opportunity Management V, LLC | 22,750 | $1,075,000 | 2.71% |
| ARMISTICE CAPITAL, LLC | 2,070,000 | $97,849,000 | 1.71% |
| Paradigm Biocapital Advisors LP | 148,216 | $7,006,000 | 1.40% |
| Foresite Capital Management V, LLC | 42,250 | $1,997,000 | 1.40% |
| RA Capital Management | 896,724 | $42,389,000 | 1.13% |
| TANG CAPITAL MANAGEMENT LLC | 137,700 | $6,509,000 | 0.99% |
| Soleus Capital Management, L.P. | 100,000 | $4,727,000 | 0.74% |
| ACUTA CAPITAL PARTNERS, LLC | 27,500 | $1,300,000 | 0.72% |